Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

January 25th 2024

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

January 24th 2024

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.

Dr Garmezy on Considerations For Frontline Treatment Selection in ccRCC

January 19th 2024

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Dr Bupathi on Updates in the Second-Line Management of Advanced RCC

January 17th 2024

Manojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.

Grivas Expands on Therapeutic Developments and Future Research Directions in GU Cancers

January 17th 2024

Petros Grivas, MD, PhD, discusses the role of PARP inhibitor regimens in prostate cancer, the importance of genetic testing in this setting, and more.

Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCC

January 16th 2024

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.

Dr Pal on the Rationale for Investigating Zanzalintinib in Relapsed/Refractory ccRCC

January 15th 2024

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC

January 15th 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Dr Giles on the Importance of Shared Decision Making When Managing GU Cancers

January 9th 2024

Rachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.

Combination Regimens Stir Excitement in Advanced RCC

January 9th 2024

Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.

Dr Jonasch on the Importance of Spotlighting Patient Advocacy in GU Malignancies

January 8th 2024

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

January 4th 2024

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

Future Outlooks in the Treatment of Advanced RCC

December 27th 2023

Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.

Data Updates in Advanced RCC from 2023 IKCS: North America

December 27th 2023

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Combination Regimens Expand RCC and Prostate Cancer Treatment Armamentariums

December 26th 2023

Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer.

Dr Rini on the FDA Approval of Belzutifan in Advanced RCC

December 21st 2023

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Approach to Collaborative Care in Bladder Cancer

December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.